Abstract: Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
Type:
Application
Filed:
January 31, 2006
Publication date:
July 6, 2006
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
Abstract: Medical implants are provided which release an anthracycline, fluoropyrimidine, folic acid antagonist, podophylotoxin, camptothecin, hydroxyurea, and/or platinum complex, thereby inhibiting or reducing the incidence of infection associated with the implant.
Type:
Application
Filed:
January 31, 2006
Publication date:
June 15, 2006
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Richard Liggins, Troy Loss
Abstract: The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.
Type:
Application
Filed:
December 5, 2005
Publication date:
June 8, 2006
Applicants:
Angiotech International AG, The University of British Columbia
Abstract: Compositions and devices including hyaluronic acid and a compound that inhibits degradation of hyaluronic acid, and methods of making and using same.
Type:
Application
Filed:
August 15, 2005
Publication date:
February 23, 2006
Applicants:
Angiotech International AG, University of British Columbia
Inventors:
William Hunter, David Gravett, Philip Toleikis, John Jackson
Abstract: Agents, compositions, and implants are provided herein for treating diverticular disease (e.g., diverticulosis and diverticulitis). In particular, fibrosis-inducing agents, hemostatic agents, and/or anti-infective agents, or compositions containing one or more of these agents are provided for use in methods for treating diverticular disease.
Type:
Application
Filed:
May 12, 2005
Publication date:
December 15, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, Philip Toleikis, David Gravett, Rui Avelar
Abstract: Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.
Abstract: Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.
Type:
Application
Filed:
November 26, 2004
Publication date:
September 22, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
Type:
Application
Filed:
November 22, 2004
Publication date:
September 22, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, Philip Toleikis, David Gravett, Arpita Maiti, Richard Liggins, Aniko Takacs-Cox, Rui Avelar, Troy Loss
Abstract: Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.
Type:
Application
Filed:
December 7, 2004
Publication date:
September 22, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.
Type:
Application
Filed:
November 26, 2004
Publication date:
September 22, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
Type:
Application
Filed:
December 7, 2004
Publication date:
September 15, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
Type:
Application
Filed:
December 1, 2004
Publication date:
September 8, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, Philip Toleikis, David Gravett, Arpita Maiti, Richard Liggins, Aniko Takacs-Cox, Rui Avelar, Troy Loss
Abstract: Implants are used in combination with a fibrosis-inducing agent in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or increase fibrosis between the implant and the host tissue.
Type:
Application
Filed:
December 7, 2004
Publication date:
September 1, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
Abstract: Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
Type:
Application
Filed:
November 30, 2004
Publication date:
September 1, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti, Pierre Signore, Richard Liggins
Abstract: Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.
Type:
Application
Filed:
December 7, 2004
Publication date:
September 1, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: A method for treating contracture is provided that includes administering to a patient in need thereof a composition that includes a therapeutic agent effective in treating contracture. Compositions, devices, and kits for use in treating contracture are also described.
Type:
Application
Filed:
January 31, 2005
Publication date:
August 25, 2005
Applicant:
Angiotech International AG
Inventors:
Rui Avelar, Richard Liggins, Philip Toleikis, Troy Loss, David Gravett, Arpita Maiti
Abstract: Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
Type:
Application
Filed:
December 7, 2004
Publication date:
August 25, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, Philip Toleikis, David Gravett, Arpita Maiti, Richard Liggins, Aniko Takacs-Cox, Rui Avelar, Troy Loss
Abstract: Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
Type:
Application
Filed:
December 7, 2004
Publication date:
August 25, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, David Gravett, Philip Toleikis, Arpita Maiti
Abstract: Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
Type:
Application
Filed:
December 2, 2004
Publication date:
August 25, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, Philip Toleikis, David Gravett, Arpita Maiti, Richard Liggins, Aniko Takacs-Cox, Rui Avelar, Troy Loss
Abstract: Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
Type:
Application
Filed:
November 29, 2004
Publication date:
August 25, 2005
Applicant:
Angiotech International AG
Inventors:
William Hunter, Philip Toleikis, David Gravett, Arpita Maiti, Richard Liggins, Aniko Takacs-Cox, Rui Avelar, Troy Loss